Objective To evaluate Cervista high-risk human papillomavirus (HR-HPV)DNA testing combined with thin cytology test (TCT)in cervical cancer screening. Methods A total of 745 female patients were diagnosed as precancerous lesions or cervical cancer with pathological diagnosis as gold standard. The performance of TCT,Cervista HR-HPV DNA testing and Cervista HR-HPV DNA testing combined with TCT were evaluated. The role of Cervista HR-HPV DNA testing combined with TCT in cervical cancer screening was evaluated. Results The specificity of TCT was the best(50.40%). The sensitivity and negative predictive value of Cervista HR-HPV DNA testing combined with TCT were 92.51% and 82.31%,which were higher than those of single determinations. Conclusions The determination rate of Cervista HR-HPV DNA testing is higher than that of TCT,the combined determination can improve the sensitivity and negative predictive valve effectively,and can decrease the rate of missed diagnosis and false positive rate.%目的 评价Cervista高危型人乳头瘤病毒(HR-HPV)DNA检测联合薄层液基细胞学检查(TCT)在宫颈癌筛查中的临床价值.方法 收集阴道镜活检病理结果为癌前病变及宫颈癌的患者745例,行TCT及Cervista HR-HPV DNA检测,以病理学诊断为金标准,比较TCT、Cervista HR-HPV DNA检测及Cervista HR-HPV DNA检测联合TCT的结果,评价Cervista HR-HPV DNA检测联合TCT在宫颈癌筛查中的临床价值.结果 TCT的特异性最高,为50.40%,而Cervista HR-HPV DNA检测联合TCT的敏感性和阴性预测值均最高,分别为92.51%、82.31%.结论 Cervista HR-HPV DNA检测对于宫颈癌的检出率较TCT高,而二者联合筛查可显著提高敏感性和阴性预测值,降低漏诊率.
展开▼
